Probably very little. Right to Try is specifically for terminal patients, and it already exists in the statutes of about 40 states. This federal statute basically just covers the other ~10 states.
In many cases, terminal patients already have this option, they just have to petition the drug companies. The FDA does have to agree, but minus some red tape, doesn’t tend to impede the process much.
Maybe the sheer visibility for clinical stage treatments could be a positive. I’m not counting on it.
News 
Market Data 
Discover 
